{"id":20592,"date":"2026-06-13T00:00:00","date_gmt":"2026-06-12T22:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=f069b7032dcffdf1980a4239d4dbe733"},"modified":"2026-06-13T00:00:00","modified_gmt":"2026-06-12T22:00:00","slug":"securities-fraud-investigation-into-erasca-inc-eras-announced-shareholders-who-lost-money-urged-to-contact-glancy-prongay-wolke-rotter-llp-a-leading-securities-fraud-law-firm","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=20592","title":{"rendered":"Securities Fraud Investigation Into Erasca, Inc. (ERAS) Announced \u2013 Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm"},"content":{"rendered":"

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP<\/a>, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Erasca, Inc. (\u201cErasca\u201d or the \u201cCompany\u201d) (NASDAQ: ERAS<\/a>) investors concerning the Company\u2019s possible violations of the federal securities laws.<\/p><\/a><\/a>

IF YOU ARE AN INVESTOR WHO LOST MONEY ON ERASCA, INC. (ERAS), CLICK <\/b>HERE<\/b><\/a> TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.<\/b><\/p>

What Happened?<\/b><\/p>

On April 27, 2026, before market hours, Erasca disclosed that it had received a letter from legal counsel for Revolution Medicines, Inc. (\u201cRevMed\u201d) alleging that Erasca\u2019s drug candidate, ERAS-0015, infringes a RevMed patent and is connected to alleged trade secret misappropriation. RevMed also claimed that Erasca had \u201cimproperly compared preclinical data of ERAS-0015 and RMC-6236 in public disclosures\u201d and demanded Erasca cease making \u201cdeceptive and untrue comparative statements comparing ERAS-0015 and RMC-6236.\u201d<\/p>

On this news, Erasca\u2019s stock price fell $2.34, or 10.9%, to close at $19.15 per share on April 27, 2026, thereby injuring investors.<\/p>

That same day, after market hours, Erasca reported preliminary Phase 1 clinical data from ERAS-0015, revealing that a patient had died approximately one month after starting ERAS-0015.<\/p>

On this news, Erasca\u2019s stock price fell $9.25, or 48.3%, to close at $9.90 per share on April 28, 2026, thereby injuring investors further.<\/p>

Contact Us To Participate or Learn More:<\/b><\/p>

If you wish to\u202flearn more\u202fabout this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.<\/p>

Charles Linehan, Esq.,Glancy Prongay Wolke & Rotter LLP,1925 Century Park East, Suite 2100,Los Angeles California 90067Email: shareholders@glancylaw.com<\/a>Telephone: 310-201-9150 (Toll-Free: 888-773-9224)Visit our website at www.glancylaw.com<\/a>.Follow us for updates on LinkedIn<\/a>, Twitter<\/a>, or Facebook<\/a>.<\/p>

Whistleblower Notice<\/b><\/p>

Persons with non-public information regarding Erasca should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@glancylaw.com<\/a>.<\/p>

About Glancy Prongay Wolke & Rotter LLP<\/b><\/p>

GPWR is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Recognizing the firm\u2019s recent successes, GPWR was named one of Law360\u2019s Securities Groups of the Year and ranked second-highest in total investor recoveries by Institutional Shareholder Services Securities Class Action Services in 2025. GPWR\u2019s lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPWR\u2019s past successes have been widely covered by leading news and industry publications such as The Wall Street Journal<\/i>, The Financial Times<\/i>, Bloomberg Businessweek<\/i>, Reuters<\/i>, the Associated Press<\/i>, Barron\u2019s<\/i>, Investor\u2019s Business Daily<\/i>, Forbes<\/i>, and Money<\/i>. Prior results do not guarantee a similar outcome.<\/p>

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p> Contacts<\/b>

Glancy Prongay Wolke & Rotter LLP,1925 Century Park East, Suite 2100,Los Angeles, CA 90067Charles Linehan<\/b>Email: shareholders@glancylaw.com<\/a>Telephone: 310-201-9150Toll-Free: 888-773-9224Visit our website at: www.glancylaw.com<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"

LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Erasca, Inc. (\u201cErasca\u201d or the \u201cCompany\u201d) (NASDAQ: ERAS) investors c…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-20592","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/20592","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20592"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/20592\/revisions"}],"predecessor-version":[{"id":20593,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/20592\/revisions\/20593"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20592"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20592"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20592"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}